A sealed folder on a hospital supply cart in a quiet clinical hallway.

Selling Indian healthcare AI to US providers without wasting the first pilot

A practical playbook for India-built healthcare AI founders to land a US provider pilot with BAA readiness, paid scope, sponsor maps, and proof.

Akhil Agrawal · September 21, 2026 · 7 min read

The short version. You get the first US provider pilot by shrinking the claim, making HIPAA boring, pricing a narrow pilot, and selling a workflow a hospital already owns. I would aim at a tight care setting, a named buyer, a data path, and a queue the team hates. Big hospital logos can wait. BAA readiness, paid scope, sponsor maps, and founder-led proof matter more than the India story.

Before you start:

Pick a specialty workflow before you pitch a hospital system
Treat the BAA as table stakes, with counsel, data maps, logs, and cloud answers ready
Sell a paid pilot with a narrow dataset and a clear stop date
Keep founder-led sales alive until provider language, proof gaps, deal risk, and next steps are plain

Step 1: Choose a care workflow until done looks like a named buyer with a painful queue

Start with the care setting before you show the model; a chief medical officer hears risk while a department lead hears the messy queue your product might clear. Pick the queue. For Indian founders, I would skip broad hospital-wide AI and aim at radiology follow-up, prior auth, scribing, leakage, coding, nurse inbox work, or another owned workflow with an obvious US buyer.

Clinical tools arranged on a stainless exam table with no visible labels.

A provider pilot needs a local reason to exist. Medicaid mix, payer rules, staffing gaps, EHR quirks, and service-line profit all change the pitch across US care settings. I map the buyer by job title and pain, then I cut any use case that needs many committees before a clinician can test it.

Named care setting
Owned workflow
Buyer with budget
Pain visible in a queue

Step 2: Make HIPAA dull until done looks like a signed BAA path

Treat HIPAA like plumbing, and make the buyer feel that nobody has to teach you the basics of protected health data, audit trails, access, and breach handling. Make it dull. HHS says a vendor that creates, receives, maintains, or sends PHI for a covered entity can be a business associate, and HHS also publishes sample BAA terms for those contracts.

Country of build matters less than data flow. A US provider will ask who signs the BAA, where PHI sits, which cloud tools see it, how offshore access works, and how fast you can revoke a user's key. Counsel should own the final paper; you should own the plain English data map before the first security call.

Signer for the BAA
PHI flow map
Cloud region and subprocessors
Audit logs
Breach playbook

Step 3: Package the pilot until done looks like a scoped paid trial

Package the pilot as a small commercial deal with a fixed workflow, named data, a stop date, and a buyer who will say what changed. Charge something. Free pilots teach the provider that your product sits in research mode, and they train your team to accept vague access, slow feedback, weak data, and missing executive air cover.

Pilot scope should fit inside the department's week. Give the buyer a before-state, a workflow owner, an agreed readout, a de-risked data path, and a kill rule for stopping early. The first hospital rarely buys AI; it buys fewer denials, cleaner notes, faster callbacks, safer triage, or a backlog that stops embarrassing the team.

Paid pilot
Start date and stop date
Success readout
Early kill rule

Step 4: Sell the provider map until done looks like an executive sponsor and a clean risk path

Sell the provider map before you sell the product, with each deal split across clinical owner, IT security, legal, finance, and the executive who can unblock a stalled pilot. Name each gate. Hospitals move when risk has a home, value has a line owner, IT has a clean path, and the signer sees why delay hurts this quarter.

If your model helps diagnose, guide care, triage, or recommend therapy, ask regulatory counsel where FDA software rules touch the claim; FDA keeps a public list of AI and machine learning enabled medical devices. NIST's AI Risk Management Framework also gives you a sober way to talk about risk, bias, monitoring, and governance without sounding like a deck full of slogans.

Clinical owner
Security reviewer
Legal signer
Finance path
Executive sponsor

Step 5: Run founder-led outbound until done looks like meetings with proof

Keep the founder in the first deals until buyer words sound natural in your mouth rather than borrowed from an investor memo. Your first messages should come from you, and I would build them around a single workflow pain, the BAA posture, the pilot shape, and a sharp proof asset. Keep it human.

A narrow account list beats mass email when each provider has a different payer mix, EHR stack, specialty line, and public priority. Inside Does cold outbound still work in 2026? Benchmarks and what gets replies I argue for reply quality over volume, and the same rule applies here with more risk on every word. For scripts, keep the founder voice tight through Founder-led sales for technical founders who have never sold while you test the wedge, title, objection set, and proof gap.

Named account list
Workflow-specific email
Proof asset
BAA line
Founder follow-up

Step 6: Turn the pilot into the first hospital until done looks like a renewal path

Run the pilot like the first renewal meeting has already been booked by the buyer, with a weekly proof log, user notes, data defects, and risk items visible. Write it down. Provider memory fades fast after a busy week, and your readout should show before-and-after work rather than screenshots of model output.

First hospital value lives after go-live. Tie the readout to renewal, expansion, support load, and workflow fit, the same muscle I break down in Retention and expansion: the GTM engine founders ignore until Series B. If the pilot works, the next ask should be a larger department path or a system vendor review rather than a vague logo slide.

Weekly proof log
User pain notes
Before-and-after workflow
Renewal path
Expansion risk

What goes wrong?

Founders lose months when they sell the model to innovation teams that cannot touch budget, data, workflow, or clinical risk. The demo feels warm, the meeting count rises, the hospital asks for another sandbox, and nobody owns the outcome after the novelty fades inside the actual department. That is drift.

Another trap is hiding India until legal finds it. State the entity, support hours, offshore access, cloud region, and subprocessor story early, then stop apologizing for where the team builds. US providers buy lower risk and better work; geography hurts only when your answers sound improvised. A fractional GTM team can help keep that story crisp across discovery, outbound, security calls, and pilot readouts while the founder still owns the deal personally.

Common questions

Do we need a BAA before a US provider pilot?

Usually, yes if your product creates, receives, maintains, or sends PHI for a covered entity. HHS treats that vendor role as a business associate, and providers expect a BAA before real data enters the product. Demo with fake data if the BAA lags. Never let a pilot depend on someone emailing charts into an unsafe side channel.

Can an Indian company sign a US provider BAA?

Yes, an Indian entity can be the signer if counsel and the provider accept the risk path, but many teams still use a US entity for payment, tax, venue, and buyer comfort. The form matters less than the controls. Providers will ask who can access PHI from India, how logs work, where data sits, and which subprocessors touch it.

Should the first provider pilot be paid?

Paid is cleaner for almost every serious pilot. A token fee still forces scope, dates, data access, and an executive readout into the open. Free work can make sense for de-identified lab work or a true research path, but a commercial pilot should teach buying behavior along with product fit.

Does FDA clearance matter before the first hospital conversation?

Sometimes, and the claim drives the answer. A tool that drafts admin work faces a different path than software that diagnoses, triages, guides care, or recommends therapy. Bring counsel in before your website, deck, and outbound imply a regulated claim you cannot support. Provider trust drops fast when regulatory language changes mid-deal.